{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:24:08Z","timestamp":1791343448972,"version":"4.3.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,5,25]],"date-time":"2016-05-25T00:00:00Z","timestamp":1464134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,5,25]],"date-time":"2016-05-25T00:00:00Z","timestamp":1464134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1038\/leu.2016.154","type":"journal-article","created":{"date-parts":[[2016,5,25]],"date-time":"2016-05-25T09:35:09Z","timestamp":1464168909000},"page":"65-74","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Effect of tyrosine kinase inhibitors on stemness in normal and chronic myeloid leukemia cells"],"prefix":"10.1038","volume":"31","author":[{"given":"L","family":"Charaf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F-X","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Lamrissi-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Moranvillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Beliveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Cardinaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Dabernat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"de Verneuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Moreau-Gaudry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Bedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,25]]},"reference":[{"key":"BFleu2016154_CR1","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"TP Hughes","year":"2003","unstructured":"Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423\u20131432.","journal-title":"N Engl J Med"},{"key":"BFleu2016154_CR2","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408\u20132417.","journal-title":"N Engl J Med"},{"key":"BFleu2016154_CR3","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, R\u00e9a D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029\u20131035.","journal-title":"Lancet Oncol"},{"key":"BFleu2016154_CR4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc3317","volume":"12","author":"T O\u2019Hare","year":"2012","unstructured":"O\u2019Hare T, Zabriskie MS, Eiring AM, Deininger MW . Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer 2012; 12: 513\u2013526.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2016154_CR5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood.V99.1.319","volume":"99","author":"SM Graham","year":"2002","unstructured":"Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, Holyoake TL . Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319\u2013325.","journal-title":"Blood"},{"key":"BFleu2016154_CR6","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","volume":"101","author":"R Bhatia","year":"2003","unstructured":"Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 4701\u20134707.","journal-title":"Blood"},{"key":"BFleu2016154_CR7","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","volume":"118","author":"JC Chomel","year":"2011","unstructured":"Chomel JC, Bonnet ML, Sorel N, Bertrand A, Meunier MC, Fichelson S et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood 2011; 118: 3657\u20133660.","journal-title":"Blood"},{"key":"BFleu2016154_CR8","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger M, Druker BJ . Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011; 121: 396\u2013409.","journal-title":"J Clin Invest"},{"key":"BFleu2016154_CR9","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","volume":"119","author":"A Hamilton","year":"2012","unstructured":"Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 2012; 119: 1501\u20131510.","journal-title":"Blood"},{"key":"BFleu2016154_CR10","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1182\/blood-2009-04-215376","volume":"115","author":"M Schemionek","year":"2010","unstructured":"Schemionek M, Elling C, Steidl U, Baumer N, Hamilton A, Spieker T et al. BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood 2010; 115: 3185\u20133195.","journal-title":"Blood"},{"key":"BFleu2016154_CR11","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","volume":"107","author":"M Copland","year":"2006","unstructured":"Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107: 4532\u20134539.","journal-title":"Blood"},{"key":"BFleu2016154_CR12","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","volume":"109","author":"HG J\u00f8rgensen","year":"2007","unstructured":"J\u00f8rgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL . Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 2007; 109: 4016\u20134019.","journal-title":"Blood"},{"key":"BFleu2016154_CR13","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1002\/stem.1748","volume":"32","author":"F Pellicano","year":"2014","unstructured":"Pellicano F, Scott MT, Helgason GV, Hopcroft LEM, Allan EK, Aspinall-O\u2019Dea M et al. The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors. Stem Cells 2014; 32: 2324\u20132337.","journal-title":"Stem Cells"},{"key":"BFleu2016154_CR14","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861\u2013872.","journal-title":"Cell"},{"key":"BFleu2016154_CR15","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1126\/science.1151526","volume":"318","author":"J Yu","year":"2007","unstructured":"Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917\u20131920.","journal-title":"Science"},{"key":"BFleu2016154_CR16","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/nbt.3178","volume":"33","author":"AG Kotini","year":"2015","unstructured":"Kotini AG, Chang CJ, Boussaad I, Delrow JJ, Dolezal EK, Nagulapally AB et al. Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells. Nat Biotechnol 2015; 33: 646\u2013655.","journal-title":"Nat Biotechnol"},{"key":"BFleu2016154_CR17","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.1182\/blood-2013-01-478412","volume":"121","author":"S Gandre-Babbe","year":"2013","unstructured":"Gandre-Babbe S, Paluru P, Aribeana C, Chou ST, Bresolin S, Lu L et al. Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia. Blood 2013; 121: 4925\u20134929.","journal-title":"Blood"},{"key":"BFleu2016154_CR18","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.celrep.2015.09.019","volume":"13","author":"S Muleno-Navarro","year":"2015","unstructured":"Muleno-Navarro S, Sevilla A, Roman AC, Lee DF, D\u2019Souza SL, Pardo S et al. Myeloid dysregulation in a human induced pluripotent stem cell model of PTPN11-associated juvenile myelomonocytic leukemia. Cell Rep 2015; 13: 504\u2013515.","journal-title":"Cell Rep"},{"key":"BFleu2016154_CR19","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1182\/blood-2010-07-298331","volume":"117","author":"K Hu","year":"2011","unstructured":"Hu K, Yu J, Suknuntha K, Tian S, Montgomery K, Choi KD et al. Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells. Blood 2011; 117: e109\u2013e119.","journal-title":"Blood"},{"key":"BFleu2016154_CR20","doi-asserted-by":"publisher","first-page":"6234","DOI":"10.1182\/blood-2011-07-367441","volume":"119","author":"K Kumano","year":"2012","unstructured":"Kumano K, Arai S, Hosoi M, Taoka K, Takayama N, Otsu M et al. Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples. Blood 2012; 119: 6234\u20136242.","journal-title":"Blood"},{"key":"BFleu2016154_CR21","doi-asserted-by":"publisher","first-page":"e71596","DOI":"10.1371\/journal.pone.0071596","volume":"8","author":"A Bedel","year":"2013","unstructured":"Bedel A, Pasquet JM, Lippert E, Taillepierre M, Lagarde V, Dabernat S et al. Variable behavior of iPSCs derived from CML patients for response to TKI and hematopoietic differentiation. PLoS One 2013; 8: e71596.","journal-title":"PLoS One"},{"key":"BFleu2016154_CR22","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.scr.2015.10.015","volume":"15","author":"K Suknuntha","year":"2015","unstructured":"Suknuntha K, Ishii Y, Tao L, Hu K, McIntosh BE, Yang D et al. Discovery of survival factor for primitive chronic myeloid leukemia cells using induced pluripotent stem cells. Stem Cell Res 2015; 15: 678\u2013693.","journal-title":"Stem Cell Res"},{"key":"BFleu2016154_CR23","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.1158\/0008-5472.CAN-13-1318","volume":"73","author":"AS Corbin","year":"2013","unstructured":"Corbin AS, O\u2019Hare T, Gu Z, Kraft IL, Eiring AM, Khorashad JS et al. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors. Cancer Res 2013; 73: 5775\u20135786.","journal-title":"Cancer Res"},{"key":"BFleu2016154_CR24","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1182\/blood-2013-07-511907","volume":"123","author":"KP Ng","year":"2014","unstructured":"Ng KP, Manjeri A, Lee KL, Huang W, Tan SY, Chuah CTH et al. Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition. Blood 2014; 123: 3316\u20133326.","journal-title":"Blood"},{"key":"BFleu2016154_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ajhg.2012.05.026","volume":"91","author":"A Bedel","year":"2012","unstructured":"Bedel A, Taillepierre M, Guyonnet-Duperat V, Lippert E, Dubus P, Dabernat S et al. Metabolic correction of congenital erythropoietic porphyria with iPSCs free of reprogramming factors. Am J Hum Genet 2012; 91: 109\u2013121.","journal-title":"Am J Hum Genet"},{"key":"BFleu2016154_CR26","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1182\/blood.V91.9.3357","volume":"91","author":"GW Dewald","year":"1998","unstructured":"Dewald GW, Wyatt WA, Juneau AL, Carlson RO, Zinsmeister AR, Jalal SM et al. Highly sensitive fluorescence in situ hybridization method to detect double BCR\/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood 1998; 91: 3357\u20133365.","journal-title":"Blood"},{"key":"BFleu2016154_CR27","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1182\/blood-2009-07-231845","volume":"115","author":"JE Carette","year":"2010","unstructured":"Carette JE, Pruszak J, Varadarajan M, Blomen VA, Gokhale S, Camargo FD et al. Generation of iPSCs from cultured human malignant cells. Blood 2010; 115: 4039\u20134042.","journal-title":"Blood"},{"key":"BFleu2016154_CR28","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Segal GM, Fanning S, Zimmermann J, Lydon NB . Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561\u2013566.","journal-title":"Nat Med"},{"key":"BFleu2016154_CR29","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.3109\/10428194.2012.695779","volume":"53","author":"JL Steegmann","year":"2012","unstructured":"Steegmann JL, Cervantes F, Le Coutre P, Porkka K, Saglio G . Off -target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Leuk Lymphoma 2012; 53: 2351\u20132361.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2016154_CR30","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/leu.2008.364","volume":"23","author":"F Belloc","year":"2009","unstructured":"Belloc F, Airiau K, Jeanneteau M, Garcia M, Guerin E, Lippert E et al. The stem cell factor\u2013c-KIT pathway must be inhibited to enable apoptosis induced by BCR\u2013ABL inhibitors in chronic myelogenous leukemia cells. Leukemia 2009; 23: 679\u2013685.","journal-title":"Leukemia"},{"key":"BFleu2016154_CR31","doi-asserted-by":"publisher","first-page":"e253","DOI":"10.1371\/journal.pbio.0060253","volume":"6","author":"J Silva","year":"2008","unstructured":"Silva J, Barrandon O, Nichols J, Kawaguchi J, Theunissen TW, Smith A . Promotion of reprogramming to ground state pluripotency by signal inhibition. Plos Biology 2008; 6: e253.","journal-title":"Plos Biology"},{"key":"BFleu2016154_CR32","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature06968","volume":"453","author":"QL Ying","year":"2008","unstructured":"Ying QL, Wray J, Nichols J, Batlle-Morera L, Doble B, Woodgett J et al. The ground state of embryonic stem cell self-renewal. Nature 2008; 453: 519\u2013523.","journal-title":"Nature"},{"key":"BFleu2016154_CR33","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.stem.2008.05.011","volume":"2","author":"Y Shi","year":"2008","unstructured":"Shi Y, Do JT, Desponts C, Hahm HS, Scholer HR, Ding S . A combined chemical and genetic approach for the generation of Induced Pluripotent Stem Cells. Cell Stem Cell 2008; 2: 525\u2013528.","journal-title":"Cell Stem Cell"},{"key":"BFleu2016154_CR34","doi-asserted-by":"publisher","first-page":"e0127739","DOI":"10.1371\/journal.pone.0127739","volume":"10","author":"J Vrbsky","year":"2015","unstructured":"Vrbsky J, Tereh T, Kyrylenko S, Dvorak P, Krejci L . MEK and TGF-beta Inhibition promotes reprogramming without the use of transcription factor. PLoS One 2015; 10: e0127739.","journal-title":"PLoS One"},{"key":"BFleu2016154_CR35","doi-asserted-by":"publisher","first-page":"38279","DOI":"10.1074\/jbc.M112.386755","volume":"287","author":"R Spelat","year":"2012","unstructured":"Spelat R, Ferro F, Curcio F . Serine 111 phosphorylation regulates OCT4A Protein subcellular distribution and degradation. J Biol Chem 2012; 287: 38279\u201338288.","journal-title":"J Biol Chem"},{"key":"BFleu2016154_CR36","doi-asserted-by":"publisher","first-page":"7162","DOI":"10.1073\/pnas.1203874109","volume":"109","author":"J Brumbaugh","year":"2012","unstructured":"Brumbaugh J, Hou Z, Russell JD, Howden SE, Yu P, Ledvina AR et al. Phosphorylation regulates human OCT4. Proc Natl Acad Sci 2012; 109: 7162\u20137168.","journal-title":"Proc Natl Acad Sci"},{"key":"BFleu2016154_CR37","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/cr.2014.112","volume":"24","author":"G Chen","year":"2014","unstructured":"Chen G, Xu X, Zhang L, Fu Y, Wang M, Gu H, Xie X . Blocking autocrine VEGF signaling by sunitinib, an anti-cancer drug, promotes embryonic stem cell self-renewal and somatic cell reprogramming. Cell Res 2014; 24: 1121\u20131136.","journal-title":"Cell Res"},{"key":"BFleu2016154_CR38","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/nrc2900","volume":"10","author":"W Kolch","year":"2010","unstructured":"Kolch W, Pitt A . Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat Rev Cancer 2010; 10: 618\u2013629.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2016154_CR39","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","volume":"18","author":"D Cilloni","year":"2012","unstructured":"Cilloni D, Saglio G . Molecular pathways: BCR-ABL. Clin Cancer Res 2012; 18: 930\u2013937.","journal-title":"Clin Cancer Res"},{"key":"BFleu2016154_CR40","doi-asserted-by":"publisher","first-page":"18623","DOI":"10.1074\/jbc.273.29.18623","volume":"273","author":"MF Favata","year":"1998","unstructured":"Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998; 273: 18623\u201318632.","journal-title":"J Biol Chem"},{"key":"BFleu2016154_CR41","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1172\/JCI70313","volume":"124","author":"P Chaurasia","year":"2014","unstructured":"Chaurasia P, Gajzer DC, Schaniel C, D\u2019Souza S, Hoffman R . Epigenetic reprogramming induces the expansion of cord blood stem cells. J Clin Invest 2014; 124: 2378\u20132395.","journal-title":"J Clin Invest"},{"key":"BFleu2016154_CR42","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood.V95.11.3289","volume":"95","author":"A Peled","year":"2000","unstructured":"Peled A, Kollet O, Ponomaryov T, Petit I, Franitza S, Grabovsky V et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34+ cells: role in transendothelial\/stromal migration and engraftment of NOD\/SCID mice. Blood 2000; 95: 3289\u20133296.","journal-title":"Blood"},{"key":"BFleu2016154_CR43","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1084\/jem.20112087","volume":"208","author":"F Pellicano","year":"2011","unstructured":"Pellicano F, Holyoake TL . Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks. J Exp Med 2011; 208: 2155\u20132158.","journal-title":"J Exp Med"},{"key":"BFleu2016154_CR44","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/embr.201338254","volume":"15","author":"D Friedmann-Morvinski","year":"2014","unstructured":"Friedmann-Morvinski D, Verma IM . Dedifferentiation and reprogramming: origins of cancer stem cells. EMBO Rep 2014; 15: 244\u2013253.","journal-title":"EMBO Rep"},{"key":"BFleu2016154_CR45","doi-asserted-by":"publisher","first-page":"461","DOI":"10.4252\/wjsc.v7.i2.461","volume":"7","author":"EL Curry","year":"2015","unstructured":"Curry EL, Moad M, Robson CN, Heer R . Using induced pluripotent stem cells as a tool for modeling carcinogenesis. World J Stem Cells 2015; 7: 461\u2013469.","journal-title":"World J Stem Cells"},{"key":"BFleu2016154_CR46","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.molmed.2012.04.001","volume":"18","author":"V Ramos-Mejia","year":"2012","unstructured":"Ramos-Mejia V, Fraga MF, Menendez P . iPSCs from cancer cells: challenges and opportunities. Trends Mol Med 2012; 18: 245\u2013247.","journal-title":"Trends Mol Med"},{"key":"BFleu2016154_CR47","doi-asserted-by":"publisher","first-page":"6609","DOI":"10.1128\/MCB.00398-08","volume":"28","author":"A Barroso-delJesus","year":"2008","unstructured":"Barroso-delJesus A, Romero-Lopez C, Lucena-Aguilar G, Melen GJ, Sanchez L, Ligero G et al. Embryonic stem cell-specific miR302-367 cluster: human gene structure and functional characterization of its core promoter. Mol Cell Biol 2008; 28: 6609\u20136619.","journal-title":"Mol Cell Biol"},{"key":"BFleu2016154_CR48","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/gm256","volume":"3","author":"TT Onder","year":"2011","unstructured":"Onder TT, Daley GQ . microRNAs become macro players in somatic cell reprogramming. Genome Med 2011; 3: 40.","journal-title":"Genome Med"},{"key":"BFleu2016154_CR49","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.4161\/cc.19846","volume":"11","author":"I Lipchina","year":"2012","unstructured":"Lipchina I, Studer L, Betel D . The expanding role of miR302\u2013367 in pluripotency and reprogramming. Cell Cycle 2012; 11: 1517\u20131523.","journal-title":"Cell Cycle"},{"key":"BFleu2016154_CR50","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.bbagrm.2013.10.001","volume":"1839","author":"S Jerabek","year":"2014","unstructured":"Jerabek S, Merino F, Sch\u00f6ler HR, Cojocaru V . OCT4: Dynamic DNA binding pioneers stem cell pluripotency. Biochim Biophys Acta 2014; 1839: 138\u2013154.","journal-title":"Biochim Biophys Acta"},{"key":"BFleu2016154_CR51","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/stem.1278","volume":"31","author":"S Hu","year":"2013","unstructured":"Hu S, Wilson KD, Ghosh Z, Han L, Wang Y, Lan F et al. MicroRNA-302 increases reprogramming efficiency via repression of NR2F2. Stem Cells 2013; 31: 259\u2013268.","journal-title":"Stem Cells"},{"key":"BFleu2016154_CR52","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/leu.2013.304","volume":"28","author":"Y Liu","year":"2014","unstructured":"Liu Y, Cheng H, Gao S, Lu X, He F, Hu L et al. Reprogramming of MLL-AF9 leukemia cells into pluripotent stem cells. Leukemia 2014; 28: 1071\u20131080.","journal-title":"Leukemia"},{"key":"BFleu2016154_CR53","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.stem.2016.02.004","volume":"18","author":"H Zhang","year":"2016","unstructured":"Zhang H, Gayen S, Xiong J, Zhou B, Shanmugam AK, Sun Y et al. MLL1 inhibition reprograms epiblast stem cells to naive pluripotency. Cell Stem Cell 2016; 18: 481\u2013494.","journal-title":"Cell Stem Cell"},{"key":"BFleu2016154_CR54","doi-asserted-by":"publisher","first-page":"5734","DOI":"10.1002\/anie.201101042","volume":"50","author":"J Staerk","year":"2011","unstructured":"Staerk J, Lyssiotis CA, Medeiro LA, Bollong M, Foreman RK, Zhu S et al. Pan-Src family kinase inhibitors replace Sox2 during the direct reprogramming of somatic cells. Angew Chem Int Ed Engl 2011; 50: 5734\u20135736.","journal-title":"Angew Chem Int Ed Engl"},{"key":"BFleu2016154_CR55","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","volume":"111","author":"SM Pye","year":"2008","unstructured":"Pye SM, Cortes J, Ault P, Hatfield A, Kantarjian H, Pilot R et al. The effects of imatinib on pregnancy outcome. Blood 2008; 111: 5505\u20135508.","journal-title":"Blood"},{"key":"BFleu2016154_CR56","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11845-014-1084-5","volume":"184","author":"A Mukhopadhyay","year":"2015","unstructured":"Mukhopadhyay A, Dasgupta S, Ray UK, Gharami F, Bose CK et al. Pregnancy outcome in chronic myeloid leukemia patients on imatinib therapy. Ir J Med Sci 2015; 184: 183\u2013188.","journal-title":"Ir J Med Sci"},{"key":"BFleu2016154_CR57","doi-asserted-by":"publisher","first-page":"734","DOI":"10.3109\/0284186X.2011.577562","volume":"50","author":"E Shash","year":"2011","unstructured":"Shash E, Bassi S, Cocorocchio E, Colpi GM, Cinieri S et al. Fatherhood during imatinib. Acta Oncol 2011; 50: 734\u2013735.","journal-title":"Acta Oncol"},{"key":"BFleu2016154_CR58","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1158\/1535-7163.MCT-07-0042","volume":"7","author":"L Jin","year":"2008","unstructured":"Jin L, Tabe Y, Konoplev S, Xu Y, Leysath CE, Lu H et al. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther 2008; 7: 48\u201358.","journal-title":"Mol Cancer Ther"},{"key":"BFleu2016154_CR59","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nature15248","volume":"525","author":"S Prost","year":"2015","unstructured":"Prost S, Relouzat F, Spentchian M, Ouzegdouh Y, Saliba J, Massonnet G et al. Erosion of the chronic myeloid leukemia stem cell pool by PPAR\u03b3 agonists. Nature 2015; 525: 380\u2013383.","journal-title":"Nature"},{"key":"BFleu2016154_CR60","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/nature07815","volume":"458","author":"MAG Essers","year":"2009","unstructured":"Essers MAG, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA, Trumpp A . IFNa activates dormant haematopoietic stem cells in vivo. Nature 2009; 458: 904\u2013908.","journal-title":"Nature"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2016154.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2016154","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2016154.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:21:36Z","timestamp":1648743696000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2016154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,25]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["BFleu2016154"],"URL":"https:\/\/doi.org\/10.1038\/leu.2016.154","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,25]]},"assertion":[{"value":"5 January 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}